Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  IXICO plc    IXI   GB00BFXR4C20

IXICO PLC

(IXI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/20/2021 01/21/2021 01/22/2021 01/25/2021 01/26/2021 Date
89.5(c) 89.5(c) 86.5(c) 80.8(c) 84.5 Last
58 584 44 219 124 203 199 980 162 034 Volume
0.00% 0.00% -3.35% -6.59% +4.58% Change
More quotes
Financials
Sales 2020 9,32 M 12,8 M 12,8 M
Net income 2020 0,70 M 0,97 M 0,97 M
Net cash position 2020 7,65 M 10,5 M 10,5 M
P/E ratio 2020 53,9x
Yield 2020 -
Sales 2021 10,0 M 13,7 M 13,7 M
Net income 2021 0,71 M 0,98 M 0,98 M
Net cash position 2021 6,30 M 8,65 M 8,65 M
P/E ratio 2021 53,9x
Yield 2021 -
Capitalization 38,1 M 52,0 M 52,3 M
EV / Sales 2020 3,27x
EV / Sales 2021 3,18x
Nbr of Employees 82
Free-Float 61,9%
More Financials
Company
IXICO plc is a brain health company. The Company's brain health focus includes Alzheimer's disease, Huntington's disease, Parkinson's disease, behavioral health and adolescent mental health. It is a provider of clinical trials services to pharmaceutical companies. Its products include Assessa, mehealth, MyBrainBook and TrialTracker. Assessa is a decision-support tool for healthcare professionals looking to diagnose... 
More about the company
Notations Surperformance© of IXICO plc
Trading Rating : - Investor Rating :
More Ratings
All news about IXICO PLC
2020IXICO : Expands Rare Disease Franchise With $5 Million Contract Win
MT
2020IXICO Secures Contract for Orphan Drug Clinical Trial for Huntington's Diseas..
MT
2020Earnings Flash (IXI.L) IXICO Reports FY20 Revenue GBP9.5M
MT
2020Earnings Flash (IXI.L) IXICO Posts FY20 EPS GBX2.00
MT
2020IXICO Receives New Contract for Huntington's Disease Study
MT
2020IXICO Rises 5% on Clinical Trials Contracts for Alzheimer's Disease
MT
2020IXICO : to Present AI Segmentation Research
PU
2020IXICO : to Present at Innovation Forum
PU
2020IXICO : Supports the AD Neuroimaging Initiative
PU
2019IXICO : to Present at Alzheimer's Disease Congress
PU
More news
News in other languages on IXICO PLC
2020Du rouge en vue à Wall Street dans un climat d'aversion au risque
More news
Chart IXICO PLC
Duration : Period :
IXICO plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IXICO PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 117,00 GBX
Last Close Price 80,80 GBX
Spread / Highest target 44,8%
Spread / Average Target 44,8%
Spread / Lowest Target 44,8%
EPS Revisions
Managers and Directors
NameTitle
Giulio Cerroni Chief Executive Officer & Executive Director
Charles Alexander Evan Spicer Non-Executive Chairman
Grant Robert Nash CFO, Secretary & Executive Director
Michelle Lax Vice President-Clinical Operations
John Bradshaw Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
IXICO PLC-21.17%52
MODERNA, INC.40.71%58 169
LONZA GROUP AG6.79%50 766
CELLTRION, INC.-10.58%39 697
IQVIA HOLDINGS INC.2.15%35 090
SEAGEN INC.2.84%32 583